APCCC 2024, metastatic hormone-sensitive prostate cancer (mHSPC), androgen deprivation therapy (ADT), Androgen receptor pathway inhibitor (ARPI), Ideal Sequence After ADT plus ARPI plus Docetaxel for mHSPC, PEACE-1 trial, ARASENS trial, cabazitaxel, CARD trial, PARP inhibitors, PROfound trial, LuPSMA, VISION trial, RADIANT trial, bone-protecting agent, denosumab. Read this story
